[1] Andrade JG, Champagne J, Dubuc M, et al. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial. Circulation 2019; 140: 1779−1788. doi: 10.1161/CIRCULATIONAHA.119.042622 [2] Akkaya E, Berkowitsch A, Zaltsberg S, et al. Safety and feasibility of percutaneous skin closure using purse-string suture compared with compression bandage after pulmonary vein isolation. J Cardiovasc Electrophysiol 2017; 28: 1048−1057. doi: 10.1111/jce.13271 [3] Deshmukh A, Patel NJ, Pant S, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93, 801 procedures. Circulation 2013; 128: 2104−2112. doi: 10.1161/CIRCULATIONAHA.113.003862 [4] Burstein B, Barbosa RS, Kalfon E, et al. Venous thrombosis after electrophysiology procedures: a systematic review. Chest 2017; 152: 574−586. doi: 10.1016/j.chest.2017.05.040 [5] Das R, Ahmed K, Athanasiou T, et al. Arterial closure devices versus manual compression for femoral haemostasis in interventional radiological procedures: a systematic review and meta-analysis. Cardiovasc Intervent Radiol 2011; 34: 723−738. doi: 10.1007/s00270-010-9981-0 [6] Prada-Delgado Ó, Estévez-Loureiro R, Calviño-Santos R, et al. Safety and efficacy of femoral vascular closure devices in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am Heart J 2011; 161: 1207−1213. doi: 10.1016/j.ahj.2011.03.009 [7] Griese DP, Reents W, Diegeler A, et al. Simple, effective and safe vascular access site closure with the double-ProGlide preclose technique in 162 patients receiving transfemoral transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2013; 82: E734−E741. doi: 10.1002/ccd.25053 [8] Geis NA, Pleger ST, Chorianopoulos E, et al. Feasibility and clinical benefit of a suture-mediated closure device for femoral vein access after percutaneous edge-to-edge mitral valve repair. EuroIntervention 2015; 10: 1346−1353. doi: 10.4244/EIJV10I11A231 [9] Hamid T, Rajagopal R, Pius C, et al. Preclosure of large-sized venous access sites in adults undergoing transcatheter structural interventions. Catheter Cardiovasc Interv 2013; 81: 586−590. doi: 10.1002/ccd.24358 [10] Chinese Society of Pacing and Electrophysiology, Chinese Society of Arrhythmia. [Cryoballoon ablation of atrial fibrillation: consensus of Chinese experts]. Chin J Cardiac Arrhyth 2020; 34: 95−108. [In Chinese]. doi: 10.13333/j.cnki.cjcpe.2020.02.001 [11] Wiley JM, White CJ, Uretsky BF. Noncoronary complications of coronary intervention. Catheter Cardiovasc Interv 2002; 57: 257−265. doi: 10.1002/ccd.10307 [12] Kumar V, Wish M, Venkataraman G, et al. A randomized comparison of manual pressure versus figure-of-eight suture for hemostasis after cryoballoon ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2019; 30: 2806−2810. doi: 10.1111/jce.14252 [13] Noori VJ, Eldrup-Jørgensen J. A systematic review of vascular closure devices for femoral artery puncture sites. J Vasc Surg 2018; 68: 887−899. doi: 10.1016/j.jvs.2018.05.019 [14] Zakko J, Scali S, Beck AW, et al. Percutaneous thoracic endovascular aortic repair is not contraindicated in obese patients. J Vasc Surg 2014; 60: 921−928. doi: 10.1016/j.jvs.2014.04.051 [15] Power D, Schäfer U, Guedeney P, et al. Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: a post hoc analysis from the BRAVO-3 randomized trial. Catheter Cardiovasc Interv 2019; 93: 1374−1381. doi: 10.1002/ccd.28295 [16] Del Prete A, Della Rocca DG, Calcagno S, et al. Perclose Proglide™ for vascular closure. Future Cardiol 2021; 17: 269−282. doi: 10.2217/fca-2020-0065 [17] Ozawa A, Chaturvedi R, Lee KJ, et al. Femoral vein hemostasis in children using a suture-mediated closure device. J Interv Cardiol 2007; 20: 164−167. doi: 10.1111/j.1540-8183.2007.00241.x [18]

Mylonas I, Sakata Y, Salinger M, et al. The use of percutaneous suture-mediated closure for the management of 14 French femoral venous access. J Invasive Cardiol 2006; 18: 299−302.

[19] Shaw JA, Dewire E, Nugent A, et al. Use of suture-mediated vascular closure devices for the management of femoral vein access after transcatheter procedures. Catheter Cardiovasc Interv 2004; 63: 439−443. doi: 10.1002/ccd.20190 [20] Kar S, Hermiller J, Conn K, et al. CRT-200.28 The use of the Perclose Proglide suture mediated closure (SMC) device for vein artery access site closure up to 24 F sheaths. JACC Cardiovasc Interv 2018; 11: S35. doi: 10.1016/j.jcin.2018.01.112 [21] Hamid T, Rajagopal R, Pius C, et al. Preclosure of large-sized venous access sites in adults undergoing transcatheter structural interventions. Catheter Cardiovasc Interv 2013; 81: 586−590. doi: 10.1002/ccd.24358 [22] Akkaya E, Sözener K, Rixe J, et al. Venous access closure using a purse-string suture without heparin antagonism or additional compression after MitraClip implantation. Catheter Cardiovasc Interv 2020; 96: 179−186. doi: 10.1002/ccd.28534 [23] Velagic V, Mugnai G, Pasara V, et al. Use of figure of eight suture for groin closure with no heparin reversal in patients undergoing cryoballoon ablation for atrial fibrillation. J Interv Card Electrophysiol 2021; 60: 433−438. doi: 10.1007/s10840-020-00776-0 [24] Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2018; 20: e1−e160. doi: 10.1093/europace/eux274 [25] Nakamura R, Okishige K, Shigeta T, et al. Clinical comparative study regarding interrupted and uninterrupted dabigatran therapy during perioperative periods of cryoballoon ablation for paroxysmal atrial fibrillation. J Cardiol 2019; 74: 150−155. doi: 10.1016/j.jjcc.2019.02.003 [26] Bagoly Z, Hajas O, Urbancsek R, et al. Uninterrupted dabigatran administration provides greater inhibition against intracardiac activation of hemostasis as compared to vitamin K antagonists during cryoballoon catheter ablation of atrial fibrillation. J Clin Med 2020; 9: 3050. doi: 10.3390/jcm9093050 [27] Nakamura R, Okishige K, Shigeta T, et al. Clinical comparative study regarding interrupted and uninterrupted dabigatran therapy during perioperative periods of cryoballoon ablation for paroxysmal atrial fibrillation. J Cardiol 2019; 74: 150−155. doi: 10.1016/j.jjcc.2019.02.003 [28] Ando M, Inden Y, Yoshida Y, et al. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels 2019; 34: 1533−1541. doi: 10.1007/s00380-019-01370-9 [29] Matsunaga-Lee Y, Egami Y, Yanagawa K, et al. Limited efficacy of a figure-of-eight suture for hemostasis after cryoballoon atrial fibrillation ablation with uninterrupted oral anticoagulants. J Cardiol 2020; 76: 30−34. doi: 10.1016/j.jjcc.2020.01.012 [30] Lakshmanadoss U, Wong WS, Kutinsky I, et al. Figure-of-eight suture for venous hemostasis in fully anticoagulated patients after atrial fibrillation catheter ablation. Indian Pacing Electrophysiol J 2017; 17: 134−139. doi: 10.1016/j.ipej.2017.02.003